Royal Bank of Canada’s Lexaria Bioscience LEXX Stock Holding History

Royal Bank of Canada’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6K	Sell	476 -10	-2%	-$109	﹤0.01%	6371
2025 Q4	$4K	Hold	486	–	–	﹤0.01%	6774
2025 Q3	$7K	Hold	486	–	–	﹤0.01%	6603
2025 Q2	$6K	Hold	486	–	–	﹤0.01%	6604
2025 Q1	$12K	Hold	486	–	–	﹤0.01%	6099
2024 Q4	$15K	Hold	486	–	–	﹤0.01%	6227
2024 Q3	$22K	Hold	486	–	–	﹤0.01%	6071
2024 Q2	$20K	Hold	486	–	–	﹤0.01%	6074
2024 Q1	$26K	Buy	486 +460	+1,769%	+$17.6K	﹤0.01%	5805
2023 Q4	$0	Hold	26	–	–	﹤0.01%	7367
2023 Q3	$0	Hold	26	–	–	﹤0.01%	7339
2023 Q2	$0	Hold	26	–	–	﹤0.01%	7462
2023 Q1	$1K	Hold	26	–	–	﹤0.01%	6903
2022 Q4	$1K	Hold	26	–	–	﹤0.01%	7045
2022 Q3	$1K	Hold	26	–	–	﹤0.01%	7213
2022 Q2	$1K	Hold	26	–	–	﹤0.01%	7147
2022 Q1	$1K	Hold	26	–	–	﹤0.01%	7601
2021 Q4	$1K	Hold	26	–	–	﹤0.01%	7509
2021 Q3	$3K	Buy	26 +9	+53%	+$863	﹤0.01%	7266
2021 Q2	$2K	Sell	17 -30	-64%	-$2.68K	﹤0.01%	7251
2021 Q1	$4K	Buy	+47	New	+$4.13K	﹤0.01%	7103

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Royal Bank of Canada's LEXX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Lexaria Bioscience (LEXX) stake by 2.1% in Q1 2026, selling an estimated $109 and leaving 476 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #6371.

Royal Bank of Canada first reported a position in LEXX in Q1 2021 and has held it in 21 quarters since. The position peaked at $26K in Q1 2024. 25 funds tracked by Wall St. Rank hold LEXX as of Q1 2026.

Royal Bank of Canada held 476 shares of Lexaria Bioscience worth $6K as of Q1 2026.
Royal Bank of Canada sold 10 Lexaria Bioscience shares in Q1 2026, an estimated $109.
Lexaria Bioscience made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6371 holding.
Royal Bank of Canada first reported a position in Lexaria Bioscience in Q1 2021 and has held it in 21 quarters since.
Royal Bank of Canada's Lexaria Bioscience position peaked at $26K in Q1 2024.
25 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.